2009 SIPREC Consensus Document – Executive Summary

about

2009 SIPREC Consensus Document – Executive Summary

Item

http://www.wikidata.org/entity/Q58919775

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2010

@uk

name

2009 SIPREC Consensus Document – Executive Summary

@en

2009 SIPREC Consensus Document – Executive Summary

@nl

type

Item

label

2009 SIPREC Consensus Document – Executive Summary

@en

2009 SIPREC Consensus Document – Executive Summary

@nl

prefLabel

2009 SIPREC Consensus Document – Executive Summary

@en

2009 SIPREC Consensus Document – Executive Summary

@nl

P1476

2009 SIPREC Consensus Document – Executive Summary

@en

P2093

Antonio Tiengo

http://www.w3.org/2001/XMLSchema#string

Augusto Zaninelli

http://www.w3.org/2001/XMLSchema#string

Claudio Borghi

http://www.w3.org/2001/XMLSchema#string

Diego Vanuzzo

http://www.w3.org/2001/XMLSchema#string

Enzo Manzato

http://www.w3.org/2001/XMLSchema#string

Gabriele Riccardi

http://www.w3.org/2001/XMLSchema#string

Massimo Chiariello

http://www.w3.org/2001/XMLSchema#string

Paolo Cavallo Perin

http://www.w3.org/2001/XMLSchema#string

Paolo Verdecchia

http://www.w3.org/2001/XMLSchema#string

Roberto Miccoli

http://www.w3.org/2001/XMLSchema#string

P2860

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force

Effect of valsartan on the incidence of diabetes and cardiovascular events

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Effect of ramipril on the incidence of diabetes.

Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment.

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

P2888

11311990-000000000-00000

P304

237-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11311990-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003280300

http://www.w3.org/2001/XMLSchema#string